Pre-made Lexatumumab benchmark antibody ( Whole mAb, anti-TNFRSF10B/TRAIL-R2 therapeutic antibody, Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Lexatumumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2), intended for the treatment of cancer.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-309-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Lexatumumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody
INN Name	Lexatumumab
Target	TRAIL-R2
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	4od2:BA
Year Proposed	2006
Year Recommended	2007
Companies	Cambridge Antibody Technology;Human Genome Sciences
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Solid tumours
Development Tech	na